Skip to main content

Dr. Lesley Seymour appointed 2025 CAHS Fellow

Dr. Lesley Seymour appointed 2025 CAHS Fellow

Congratulations to Dr. Lesley Seymour, CCTG’s IND Program Director and Deputy Director, on being named a Fellow in the Canadian Academy of Health Sciences (CAHS). Election to the Academy is one of the highest honours in the Canadian health sciences community, recognizing individuals for their exceptional contributions to advancing health research, policy, and care.

"I am honoured to be appointed as a CAHS Fellow and delighted that the contributions of Canadian Cancer Trials Group faculty and investigators have been recognized," says Dr. Seymour.

Along with the other 46 named Fellows, Dr. Seymour will advance the health sciences across her areas of expertise. “Election to the Canadian Academy of Health Sciences acknowledges outstanding contributions to the health sciences,” says Dr. Trevor Young, President, CAHS. “We are proud of these Fellows’ accomplishments, and we are honoured to welcome them to the Canadian Academy of Health Sciences.” 

Dr. Seymour is internationally recognized for her work in drug development and clinical trials methodology. She completed her training in Internal Medicine, Clinical Haematology & Medical Oncology and went on to complete her PhD, focusing on correlative studies and breast cancer. In 1996 she joined the Investigational New Drug Program at CCTG. She also holds the position of Professor and Medical Oncologist in the Department of Oncology at Queens University.

"Lesley's election as a Fellow is a testament to the impact of her work and the esteem she has earned across the cancer research community in Canada and internationally,” says Janet Dancey, Chair, Canadian Cancer Trials Group.

CCTG would also like to extend congratulations to the other CCTG network leaders who have been announced as 2025 CAHS Fellows:

  • Laura Dawson, Professor and Chair, Department of Radiation Oncology, University of Toronto; Clinician-scientist, Radiation Medicine Program, University Health Network (UHN)
  • Natasha B. Leighl, Head, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Heath Network and Sinai Health System
  • James Woodgett, President and Scientific Director, Terry Fox Research Institute; Senior Investigator at the Lunenfeld-Tanenbaum Research Institute (LTRI)